Patent-pending NRCl, NRH, NMN, and BioPeak®-NAD technologies designed to improve selected active-ingredient delivery, support differentiated product lines and create strategic value across science-driven wellness portfolios.
Advanced NAD⁺ and BioPeak® Delivery Platforms for Premium Longevity Brands
Strategic differentiation through protected NAD⁺ chemistry and BioPeak® delivery
RejuvaTech has developed patent-pending NAD⁺ precursor chemistry and BioPeak®-NAD delivery technology designed to help selected high-value active ingredients reach the body in a more useful form. The platform is focused on practical product improvement: better delivery, stronger premium positioning, potential dose-efficiency advantages where validated, and differentiated science for advanced longevity and wellness products.
This approach gives strategic partners a path to move beyond commodity ingredient sourcing and build defensible, science-backed product lines in fast-growing NAD⁺, healthy-aging, cellular-energy, and premium wellness categories.
Nanocarrier and SNEDDS-based systems engineered to enhance solubility, stability, and systemic exposure of lipophilic compounds.
BioPeak®-TR: Protected triterpenoid delivery architecture
BioPeak®-TR is a patent-pending delivery platform designed to address the primary limitations of triterpenoids and other lipophilic actives: poor aqueous solubility, instability, and limited systemic absorption.
The architecture integrates:
• Hybrid lipid–cyclodextrin nanostructures
• Self-nanoemulsifying drug delivery systems (SNEDDS)
• Controlled-release and targeted intestinal delivery strategies
• Optional permeation and bioavailability enhancement components
Preclinical and formulation modeling indicate materially improved systemic exposure relative to conventional encapsulated formats, enabling:
• Dose optimization without loss of performance
• Premium-tier reformulation of existing SKUs
• Reduced dependency on high raw-material loading
• Structural differentiation in commoditizing categories
The platform is designed for scalable GMP manufacturing and integration into oral, sublingual, and targeted-release formulations.
Advanced delivery support for NAD⁺ precursors and high-value longevity actives
BioPeak®-NAD: Coordinated delivery technology for premium formulations
BioPeak®-NAD is a patent-pending delivery platform designed to help selected active ingredients survive digestion, reach the small intestine, and become more available for absorption and use by the body. The platform is focused on NAD⁺ precursors and selected high-value longevity actives where product performance can be limited by poor absorption, degradation, metabolism, or delivery inefficiency.
BioPeak®-NAD combines multiple formulation functions into one coordinated system:
• Targeted small-intestine delivery
• Stomach protection and stabilization
• Support for improved passage across the intestinal barrier
• Reduction of active-ingredient loss before absorption
• Protection for sensitive antioxidant and redox-active compounds
• Active-specific formula design for selected supplement applications
This approach is designed to help strategic partners create stronger premium products, improve selected active-ingredient use, support more differentiated product claims after validation, and reduce dependence on commodity dose-and-price competition.
Exact active identities, formula ratios, and product-specific applications are available only under NDA and staged technical diligence.
Stabilized NRH technology for next-generation NAD⁺ product development
Stabilized NRH Platform: Future-ready NAD⁺ precursor technology
RejuvaTech is developing a stabilized NRH platform designed to support the next generation of NAD⁺ products. NRH is viewed as a highly promising reduced NAD⁺ precursor, but conventional NRH can present practical development challenges involving stability, moisture sensitivity, oxidation, powder handling, and finished-product delivery.
RejuvaTech’s platform is designed to address these challenges through protected chemistry, stabilized composition design, and product-delivery strategies that can support future premium longevity formulations.
The platform includes:
• Stabilized NRH composition technology designed to improve practical product handling and storage
• Protected chemistry and manufacturing know-how for future scale-up evaluation
• Formulation approaches designed to reduce degradation and support finished-product stability
• Delivery strategies intended to improve product performance when paired with BioPeak®-NAD
• Intellectual property coverage directed to stabilized NRH compositions, manufacturing approaches, and product applications
The commercial goal is to give a strategic partner a future-ready NAD⁺ platform that can move beyond conventional NR, NMN, and commodity precursor products. When paired with BioPeak®-NAD, stabilized NRH may support a next-generation longevity product class with stronger differentiation, premium positioning, and long-term portfolio value.
Detailed chemistry, stabilization data, sample status, manufacturing pathway, safety strategy, and product-specific applications are available only under NDA and staged technical diligence.
Scalable, cost-efficient chemistry integrated with targeted nanocarrier systems for skin regeneration, follicular activation, and telomerase support.
Proprietary Triterpenoid Synthesis & Regenerative Delivery Platform
RejuvaTech has developed a vertically integrated triterpenoid platform combining proprietary scalable synthesis with advanced nanocarrier delivery architectures.
Our chemistry program enables high-purity (≥98%) production of key regenerative triterpenoids — including cycloastragenol, asiaticoside, madecassoside, oleanolic acid, maslinic acid, and related derivatives — while materially reducing reliance on plant extraction and solvent-intensive processes
This synthesis framework is paired with bio-responsive nanocarrier systems engineered for dermal and follicular targeting
The integrated architecture includes:
- Size- and charge-optimized lipid and polymeric nanoparticles (20–500 nm)
- SNEDDS and hybrid lipid systems for enhanced solubility and systemic exposure NPA 2 final
- Controlled, pH-responsive and enzyme-triggered release mechanisms
- Delivery optimization for skin, basal epidermis, dermis, and hair follicle matrices
Performance modeling and internal testing demonstrate materially improved dermal penetration, oxidative stability, and sustained release relative to conventional topical or oral triterpenoid formats
Strategically, this platform enables:
- Structural cost compression versus botanical extraction
- Premium positioning in regenerative dermatology and longevity-adjacent skincare
- IP protection at both the synthesis and delivery levels
- Compatibility with device-assisted or energy-enhanced application protocols
The result is not simply a cosmetic formulation improvement — it is a defensible regenerative chemistry and delivery platform positioned for integration into premium skin health and longevity portfolios.
Platform-driven longevity formulation combined with GMP-ready process transfer and production interface capability.
Technical integration and scalable formulation expertise
RejuvaTech functions as a scientific formulation and integration partner for advanced longevity and bioavailability-driven products.
Our role extends beyond ingredient development. We provide structured formulation architecture, excipient selection frameworks, stability guidance, and delivery system optimization designed for seamless integration into existing GMP manufacturing environments.
Key integration capabilities include:
• Complete formulation blueprints with validated mixing sequences and excipient compatibility profiles
• Scalable pre-blend and encapsulation procedures aligned with commercial batch production
• Particle size, moisture, and flow-characterization guidance to support uniform fill weight and content consistency
• Stability-oriented packaging recommendations
• Compatibility modeling for softgel, capsule, sublingual, and delayed-release formats
Where appropriate, RejuvaTech interfaces directly with partner GMP facilities to ensure controlled technology transfer, minimizing scale-up variability and reducing execution risk.
This structured integration model enables strategic partners to move from platform validation to commercial production efficiently, without reliance on trial-and-error development cycles.
The result is a streamlined path from protected chemistry to finished, premium-tier product deployment.